Newborn population-based genetic screening may reduce pediatric cancer deaths and could be cost-effective. Testing siblings of newborns with variants (ie, cascade testing) could further improve population health. Economic studies of cascade testing have focused on adults, although evidence suggests that cost-effectiveness improves for some cancer syndromes when surveillance is initiated in younger individuals.3 Our objective was to estimate the benefits and costs of cascade testing of siblings of newborns with cancer susceptibility gene variants.
O'Brien G, Christensen KD, Sullivan HK, Stout NK, Diller L, Yeh JM, Wu AC. Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants. JAMA Netw Open. 2021 Oct 1;4(10):e2129742. doi: 10.1001/jamanetworkopen.2021.29742. PMID: 34661666.
Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants